Acute nonlymphocytic leukemia.
The discovery of cytosine arabinoside, and then the anthrocycline antibiotics, 6-thioguanine, vincristine, cyclophosphamide, and other drugs, has added to the armamentarium of known effective agents. The use of combination chemotherapy, the recognition of the need during induction for virtual marrow aplasia to obtain a remission, and recognition of the predilection of the disease for the central nervous system requiring prophylaxis constitute major advances. The impediment to long-term survival is the lack of effective maintenance therapy.
D000208:Acute Disease; D000293:Adolescent; D000380:Agranulocytosis / Q000150:complications; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002478:Cells, Cultured; D002648:Child; D002675:Child, Preschool; D002869:Chromosome Aberrations / Q000150:complications; D025063:Chromosome Disorders; D004211:Disseminated Intravascular Coagulation / Q000150:complications; D004359:Drug Therapy, Combination; D005260:Female; D006087:Graft vs Host Reaction; D006689:Hodgkin Disease / Q000150:complications; D006801:Humans; D007239:Infections / Q000150:complications; D007938:Leukemia / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D007964:Leukocytosis / Q000150:complications; D008297:Male; D009113:Muramidase / Q000652:urine; D011289:Preleukemia / Q000503:physiopathology; D013921:Thrombocytopenia / Q000150:complications; D014527:Uric Acid / Q000652:urine
D000970:Antineoplastic Agents; D014527:Uric Acid; D009113:Muramidase